Completed NA INTERVENTIONAL 2-arm NCT03300518

Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

A Randomized Study to Analysis the Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

Sponsor: Merck Sharp & Dohme LLC

Conditions Infertility

Interventions Follitropin Beta;MSD Ganirelix estradiol valerate hCG

Updated 10 times since 2017 Last updated: Jan 9, 2022 Started: Nov 15, 2017 Primary completion: Jun 18, 2021 Completion: Aug 18, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03300518, this NA trial focuses on Infertility and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA
Feb 2022 — Jun 2022 [monthly]

Completed NA
Sep 2021 — Feb 2022 [monthly]

Completed NA

Status: Recruiting → Completed

▶ Show 5 earlier versions

Jan 2021 — Sep 2021 [monthly]

Recruiting NA
Oct 2020 — Jan 2021 [monthly]

Recruiting NA
May 2019 — Oct 2020 [monthly]

Recruiting NA
Jun 2018 — May 2019 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Oct 2017 — Jun 2018 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Reproductive & Genetic Hospital of CITIC-Xiangya

Data source: Reproductive & Genetic Hospital of CITIC-Xiangya

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China